ANTHONY E. MAIDA III

Corporate Board Profile

Tech Score: 0/100

Oncotelic Therapeutics, Inc.

Filing Date	Source Excerpt
2020-06-25	Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020 (the Maida Agreement), under which Dr. Maida will assist the Company... The Company will grant to Dr. Maida 400,000 restricted shares of the Company’s Common Stock corresponding to $80,000 at the stock value of $0.20 per share, to vest on May 5, 2021. The Company will also pay Dr. Maida $15,000 per month for a minimum of 20 hours per week.

Filing Date

Source Excerpt

2020-06-25

Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020 (the Maida Agreement), under which Dr. Maida will assist the Company... The Company will grant to Dr. Maida 400,000 restricted shares of the Company’s Common Stock corresponding to $80,000 at the stock value of $0.20 per share, to vest on May 5, 2021. The Company will also pay Dr. Maida $15,000 per month for a minimum of 20 hours per week.

Data sourced from SEC filings. Last updated: 2026-02-03